|  | Ricci et al. (2014) [35] | Weroha et al. (2014) [13] | Dobbin et al. (2014) [20] | Topp et al. (2014) [22] | Current study |
---|---|---|---|---|---|---|
No. cases | Â | 34 | 168 | 34 | 12 | 9 |
Tumor types | Â | All EOC types | All EOC types | All EOC types | High-grade serous | High-grade serous |
Implantation site | SQ | Yes | No | Yes | Yes | Yes |
IP | Yes | Yes | Yes | No | No | |
IB | Yes | No | No | Yes | Yes | |
Take rate (%) | Â | 25 | 74 | 85.3 (SC), 22.2 (IP) | 83 | >90 |
Passage time (weeks) | Average | Not mentioned | Not mentioned | 10 weeks | Not mentioned | 6–12 weeks |
Passage attempts | Â | P1->6 | P1 | P1-6 | P1 | P1-4 |
Stem cell analysis | Â | No | No | ALDH1, CD44,CD133 | No | ALDH1, CD44,CD133 |
Histology comparison | Â | Yes | Yes | No | No | Yes |
Immunohistochemistry analysis | ER/PR | No | No | No | Yes | Yes |
KI67 | No | Yes | Yes | Yes | Yes | |
Mutation analysis | P53 | Yes | No | No | Yes | Yes |
Gene profile | P0 | Yes | Yes | No | No | Yes |
P1-x | Yes | P1 | No | No | P2 |